Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

MICROSTRUCTURE OF BIOPOLYMER MICRO-FIBROUS SCAFFOLD AND ITS INFLUENCE ON THE ABILITY TO RETAIN MEDICINES AND TISSUE REGENERATION.

Georgian medical news·2023
Same author

The levonorgestrel intrauterine system for prevention of endometrial cancer in women with obesity: A cost-effectiveness study.

Gynecologic oncology·2021
Same author

Monitoring the evolving impact of COVID-19 on institutional surgical services: imperative for quality improvement platforms.

The British journal of surgery·2021
Same author

Granulosa and theca cell tumor in rat's ovary after modified Biskind operation.

Experimental oncology·2020
Same author

Hyperspectral measurement of skin reflectance detects differences in the visible and near-infrared regions according to race, gender and body site.

Journal of the European Academy of Dermatology and Venereology : JEADV·2020

Related Experiment Video

Updated: Apr 7, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K

A clinically applicable molecular-based classification for endometrial cancers.

A Talhouk1, M K McConechy1, S Leung2

  • 1Department of Pathology and Laboratory Medicine, University of British Columbia and BC Cancer Agency, 509-2660 Oak Street, Vancouver, British Columbia, Canada V6H 3Z6.

British Journal of Cancer
|July 15, 2015
PubMed
Summary

A new molecular classification for endometrial carcinoma (EC) using accessible assays provides independent prognostic information. This method refines risk stratification beyond traditional clinical factors for improved treatment guidance.

More Related Videos

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells
07:46

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Published on: October 13, 2023

2.0K
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

13.9K

Related Experiment Videos

Last Updated: Apr 7, 2026

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.5K
Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells
07:46

Author Spotlight: Advancing Reproductive Immunology with a Protocol for the Quantitative Evaluation of Endometrial Immune Cells

Published on: October 13, 2023

2.0K
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
05:52

Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy

Published on: August 19, 2021

13.9K

Area of Science:

  • Gynecologic Oncology
  • Molecular Pathology
  • Cancer Genomics

Background:

  • Current morphologic classification of endometrial carcinomas (ECs) lacks prognostic and predictive accuracy.
  • The Cancer Genome Atlas (TCGA) identified molecular subtypes of ECs with distinct prognoses.
  • A need exists for clinically applicable molecular classification of ECs.

Purpose of the Study:

  • To develop and validate surrogate molecular assays for EC classification based on TCGA findings.
  • To compare molecular classification with traditional clinical risk stratification.
  • To assess the prognostic value of a novel molecular classifier for EC.

Main Methods:

  • Utilized TCGA genomic data to identify key molecular drivers for EC classification.
  • Developed surrogate assays including mismatch repair protein IHC, POLE mutation analysis, and p53 IHC.
  • Validated the molecular classifier on an independent cohort of 152 EC cases, comparing it with clinical risk groups.

Main Results:

  • Multiple molecular classification models successfully replicated TCGA survival curves.
  • The validated classifier, using mismatch repair protein IHC, POLE mutation analysis, and p53 IHC, showed significant association with clinical outcomes.
  • Molecular classification provided independent prognostic information, differing in risk group composition compared to clinical stratification.
  • Combining molecular and clinicopathologic features yielded the highest accuracy in predicting patient outcomes.

Conclusions:

  • Clinically applicable molecular classification of ECs is feasible using formalin-fixed paraffin-embedded samples.
  • This molecular approach offers independent prognostic value beyond established risk factors.
  • The developed classification tool can guide individual treatment decisions and stratify patients for clinical trials.